Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i (ACHIEVE-SGLT2i) Registry
Leiden University Medical Center
Summary
This real-world, international registry aims to evaluate the current experience with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease (ACHD) patients by investigating the prescription patterns, safety, tolerability, and potential beneficial effects on heart failure-related outcomes.
Description
In the adult congenital heart disease (ACHD) population, heart failure currently represents the main cause of morbidity and mortality. The etiology of ACHD-related heart failure is heterogenous, and there is limited evidence for pharmacological treatment options for this population. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a novel pillar in the treatment of conventional LV heart failure. SGLT2i have been shown to reduce the risk of worsening heart failure and cardiovascular-related death in patients with LV heart failure. While the exact mechanisms of action are still to be elu…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Congenital heart defect. * Age ≥ 18 years. * Initiated on treatment with an SGLT2i. Exclusion Criteria: \- No consent for data collection.
Interventions
- DrugSGLT2 inhibitors
Treatment with any type and dose of sodium-glucose cotransporter 2 inhibitor.
Locations (11)
- Johns Hopkins UniversityBaltimore, Maryland
- Helen DeVos Children's HospitalGrand Rapids, Michigan
- Mount Sinai Fuster Heart HospitalNew York, New York
- Heart Center Duisburg (Evangelical Hospital Niederrhein)Duisburg
- Leiden University Medical Center (LUMC)Leiden, South Holland
- Amsterdam University Medical CenterAmsterdam